Biomarkers in COPD

Clinics in Chest Medicine

Volumn 35, Issue 1, 2014, Pages 131-141

  Agusti, Alvar ^a   Sin, Don D ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chronic bronchitis; Emphysema; Outcomes; Smoking; Treatment

Indexed keywords

CHRONIC BRONCHITIS; EMPHYSEMA; OUTCOMES; SMOKING; TREATMENT;

BIOLOGICAL MARKERS; FIBRINOGEN; HUMANS; INFLAMMATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; UTEROGLOBIN;

EID: 84893810882     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.09.006     Document Type: Review

References (49)

1. Agusti A., Calverley P., Celli B., et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122-136.
2. Rabe K.F., Hurd S., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
3. Agusti A., Sobradillo P., Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med 2011, 183:1129-1137.
4. Vestbo J., Hurd S.S., Agusti A.G., et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013, 187(4):347-365.
5. Jones P.W., Agusti A.G.N. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:822-832.
6. Vestbo J., Hurd S.S., Agusti A.G., et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, gold executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
7. Vestbo J., Edwards L.D., Scanlon P.D., et al. Changes in forced expiratory volume in 1 second over time in COPD. NEngl J Med 2011, 365:1184-1192.
8. Celli B.R., Cote C.G., Marin J.M., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. NEngl J Med 2004, 350:1005-1012.
9. Cazzola M., MacNee W., Martinez F.J., et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
10. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115:949-952.
11. Stockley R.A. Biomarkers in COPD: time for a deep breath. Thorax 2007, 62:657-660.
12. Duvoix A., Dickens J., Haq I., et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013, 68:670-676.
13. Danesh J., Lewington S., Thompson S.G., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-1809.
14. Valvi D., Mannino D.M., Mullerova H., et al. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis 2012, 7:173-182.
15. Celli B.R., Locantore N., Yates J., et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1065-1072.
16. Hurst J.R., Vestbo J., Anzueto A., et al. Susceptibility toexacerbation in chronic obstructive pulmonary disease. NEngl J Med 2010, 363:1128-1138.
17. Groenewegen K.H., Postma D.S., Hop W.C., et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133:350-357.
18. Dahl M., Tybjaerg-Hansen A., Vestbo J., et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1008-1011.
19. Polatli M., Cakir A., Cildag O., et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. JThromb Thrombolysis 2008, 26:97-102.
20. Koutsokera A., Kiropoulos T.S., Nikoulis D.J., et al. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med 2009, 103:919-926.
21. Valipour A., Schreder M., Wolzt M., et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008, 115:225-232.
22. Bozinovski S., Hutchinson A., Thompson M., et al. Serum amyloid as a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:269-278.
23. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. JAm Coll Cardiol 2007, 49:2129-2138.
24. Gan W.Q., Man S.F., Senthilselvan A., et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
25. Man S.F., Connett J.E., Anthonisen N.R., et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853.
26. Dahl M., Vestbo J., Lange P., et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255.
27. Hurst J.R., Donaldson G.C., Perera W.R., et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:867-874.
28. Thomsen M., Dahl M., Lange P., et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:982-988.
29. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? the potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.
30. Dickens J.A., Miller B.E., Edwards L.D., et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011, 12:146.
31. Wu L., Ma L., Nicholson L.F., et al. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 2011, 105:329-336.
32. Miniati M., Monti S., Basta G., et al. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011, 12:37.
33. Smith D.J., Yerkovich S.T., Towers M.A., et al. Reduced soluble receptor for advanced glycation end products in chronic obstructive pulmonary disease. Eur Respir J 2011, 37:516-522.
34. Horsfall L.J., Rait G., Walters K., et al. Serum bilirubin and risk of respiratory disease and death. JAMA 2011, 305:691-697.
35. Lomas D.A., Silverman E.K., Edwards L.D., et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009, 34:95-102. Tal-Singer, and on behalf of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigatorsand on behalf of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators.
36. Sin D.D., Man S.F.P., Marciniuk D.D., et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:1207-1214.
37. Hill J., Heslop C., Man S.F., et al. Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. Eur Heart J 2011, 32:1918-1925.
38. Lomas D.A., Silverman E.K., Edwards L.D., et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008, 63:1058-1063.
39. Yoon H.I., Li Y., Man S.F., et al. The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin. Chest 2012, 142:893-899.
40. Bafadhel M., McKenna S., Terry S., et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:48-55.
41. Aaron S.D., Vandemheen K.L., Maltais F., et al. TNFa antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax 2013, 68:142-148.
42. Serhan C.N., Brain S.D., Buckley C.D., et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007, 21:325-332.
43. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. NEngl J Med 2004, 350:2645-2653.
44. Cosio M., Saetta M., Agusti A. Immunological aspects of COPD. NEngl J Med 2009, 360:2445-2454.
45. Noguera A., Gomez C., Faner R., et al. An investigation of the resolution of inflammation (catabasis) in COPD. Respir Res 2012, 13:101.
46. Agusti A., Edwards L.D., Rennard S.I., et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012, 7:e37483.
47. Barabasi A.L., Gulbahce N., Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011, 12:56-68.
48. Divo M., Cote C., de Torres J.P., et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:155-161.
49. Kaptoge S., Di A.E., Lowe G., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.